Antimalarial medicine are used for the treatment and bar of malaria infection. This market has been growing in recent years because of the high prevalence of malaria, particularly in developing and underdeveloped countries. according to the “World protozoal infection Report 2018” by World Health Organization (WHO), there have been an estimated 219 million cases and nearly 435,000 malaria-related deaths in 2017. Hence, the high prevalence of protozoal infection is driving the expansion of this market.
The other factors include the rise in awareness initiatives by governments and research for brand new anti-malarial drugs and therapies that are serving to this market grow. However, side-effects of anti-malarial medicine and therefore the presence of counterfeit and substandard drugs are restraining the general growth of this market.
| Report Metric | Details |
| Market size available for years | 2023–2030 |
| Base year considered | 2023 |
| Forecast period | 2024–2030 |
| Forecast unit | Value (USD Million) |
| Segments covered | Drug Type, Route of Administration, Distribution Channel and Region |
| Regions covered | North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA) |
| Companies covered | Mylan Labs ,Cipla ,GlaxoSmithKline,Novartis ,Roche ,Bayer AG,Lincoln Pharmaceuticals , Strides Pharma Science, Glenmark Pharmaceuticals,Alliance Pharmaceuticals. |
The covid-19 Impact on Anti-malarial Drugs Market:
Whereas, the chemicals and accouterments sectors were relatively affected during the pandemic. This is primarily due to uncut demand for chemicals for healthcare, life wisdom, and drawing agents. However, other elements of chemical and material sectors such as types of paints, industrial oil, construction materials are facing reduction in demand. Strict lockdown reflected in a nearly 50-60% reduction in force for raw supply and availability, which directly affected the manufacturing process. Further, halt on numerous end-use diligence directly affected the chemical demand each around the world.
Anti-malarial Drugs Market Segment Overview
By Drug type , aminoquinoline segment is predicted to witness significant growth within the anti-malaria drugs market over the forecast period, owing to the increasing number of product approvals and launches for this drug during this drug class.
By Route of Administration , Oral and Injectable segment accounted market share throughout the forecast period.
By Distribution Channel ,the retail pharmacy segment is calculable to remain highest throughout the forecast period.
Market Analysis, Insights and Forecast – By Drug Type
· Aminoquinolines
· Quinoline-methanol (4-quinolinemethanols)
· Cinchona Alkaloids
· Biguanides
· Sulfonamides and sulfones
· Others
Market Analysis, Insights and Forecast – By Route of Administration
· Oral
· Injectable
Market Analysis, Insights and Forecast – By Distribution Channel
· Hospital Pharmacies
· Retail Pharmacies
· Online Pharmacies
Anti-malarial Drugs Market Regional Overview
Region-wise, in terms of regions ,The Middle East and Africa are accounted for Africa market share and are expected to continue this trend, because of a rapid surge within the prevalence of malaria within the region. in step with the world Health Organization (WHO), there have been calculable 228 million cases of protozoal infection worldwide in 2018, out of that UN agency African Region carried a disproportionately high share of the worldwide malaria burden. thus the center East and Africa region are expected to possess one in every of the biggest shares within the total anti-malarial medicine market.
On the opposite aspect, Asia-Pacific is additionally calculable to register the quickest growth thanks to the rise in awareness concerning the employment of antiprotozoal medicine for early designation of the infection for higher treatment.
Anti-malarial Drugs -market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Anti-malarial Drugs Market Competitor overview
Some key developments and strategies adopted by manufacturers in the Anti-malarial Drugs are highlighted below.
· In 2023, Shin Poong Pharmaceutical Co.Ltd, South Korea, and Medicines for malaria Venture (MMV) launched Pyramax, associate anti-malarial drug combination of pyronardine and artesunate, in Uganada.
Anti-malarial Drugs Market, Key Players -
· Mylan Labs
· Cipla
· GlaxoSmithKline
· Novartis
· Roche
· Bayer AG
· Lincoln Pharmaceuticals
· Strides Pharma Science
· Glenmark Pharmaceuticals
· Alliance Pharmaceuticals
Frequently Asked Questions (FAQ) :
Q1. What is the total CAGR expected to be recorded for the Anti-malarial Drugs market during the forecast period?
Q2. Which segment is projected to hold the largest share in the Anti-malarial Drugs Market?
Q3. What are the driving factors for the Anti-malarial Drugs market?
Q4. Which Segments are covered in the Anti-malarial Drugs market report?
Q5. Which are the prominent players offering Fuel Dispenser?
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Anti-malarial Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Drug Type
- 5.2.1. Aminoquinolines
- 5.2.2. Quinoline-methanol (4-quinolinemethanols)
- 5.2.3. Cinchona Alkaloids
- 5.2.4. Biguanides
- 5.2.5. Sulfonamides and sulfones
- 5.2.6. Others
- 5.3. Market Analysis, Insights and Forecast – By Route of Administration
- 5.3.1. Oral
- 5.3.2. Injectable
- 5.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.4.1. Hospital Pharmacies
- 5.4.2. Retail Pharmacies
- 5.4.3. Online Pharmacies
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America, Middle East, and Africa
6. North America Anti-malarial Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Drug Type
- 6.2.1. Aminoquinolines
- 6.2.2. Quinoline-methanol (4-quinolinemethanols)
- 6.2.3. Cinchona Alkaloids
- 6.2.4. Biguanides
- 6.2.5. Sulfonamides and sulfones
- 6.2.6. Others
- 6.3. Market Analysis, Insights and Forecast – By Route of Administration
- 6.3.1. Oral
- 6.3.2. Injectable
- 6.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.4.1. Hospital Pharmacies
- 6.4.2. Retail Pharmacies
- 6.4.3. Online Pharmacies
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. UK
- 6.5.2. Germany
- 6.5.3. France
- 6.5.4. Italy
- 6.5.5. Spain
- 6.5.6. Russia
- 6.5.7. Rest of Europe
7. Asia Pacific Anti-malarial Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Drug Type
- 7.2.1. Aminoquinolines
- 7.2.2. Quinoline-methanol (4-quinolinemethanols)
- 7.2.3. Cinchona Alkaloids
- 7.2.4. Biguanides
- 7.2.5. Sulfonamides and sulfones
- 7.2.6. Others
- 7.3. Market Analysis, Insights and Forecast – By Route of Administration
- 7.3.1. Oral
- 7.3.2. Injectable
- 7.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.4.1. Hospital Pharmacies
- 7.4.2. Retail Pharmacies
- 7.4.3. Online Pharmacies
- 7.5. Market Analysis, Insights and Forecast – By Country
- 7.5.1. China
- 7.5.2. India
- 7.5.3. Japan
- 7.5.4. Australia
- 7.5.5. South East Asia
- 7.5.6. Rest of Asia Pacific
8. Latin America, Middle East, and Africa Anti-malarial Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Drug Type
- 8.2.1. Aminoquinolines
- 8.2.2. Quinoline-methanol (4-quinolinemethanols)
- 8.2.3. Cinchona Alkaloids
- 8.2.4. Biguanides
- 8.2.5. Sulfonamides and sulfones
- 8.2.6. Others
- 8.3. Market Analysis, Insights and Forecast – By Route of Administration
- 8.3.1. Oral
- 8.3.2. Injectable
- 8.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.4.1. Hospital Pharmacies
- 8.4.2. Retail Pharmacies
- 8.4.3. Online Pharmacies
- 8.5. Market Analysis, Insights and Forecast – By Country
- 8.5.1. Brazil
- 8.5.2. Saudi Arabia
- 8.5.3. UAE
- 8.5.4. Rest of LAMEA
9. Competitive Analysis
- 9.1. Company Market Share Analysis, 2018
- 9.2. Key Industry Developments
- 9.3. Company Profile
- 9.4. Mylan Labs
- 9.4.1. Business Overview
- 9.4.2. Segment 1 & Service Offering
- 9.4.3. Overall Revenue
- 9.4.4. Geographic Presence
- 9.4.5. Recent Development
- 9.5. •Cipla
- 9.6. •GlaxoSmithKline
- 9.7. •Novartis
- 9.8. •Roche
- 9.9. •Bayer AG
- 9.10. •Lincoln Pharmaceuticals
- 9.11. •Strides Pharma Science
- 9.12. •Glenmark Pharmaceuticals
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
